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ABSTRACT
Statins is HMG-CoA inhibitors which used for decreasing plasma cholesterol levels and 
preventing coronary artery disease. Preclinical and clinical studies showed that statin could 
decrease the risk of cancer. This study was performed to evaluate the cytotoxic activity 
of simvastatin on T47D breast cancer cell lines and its effect in cyclin D1 expression and 
apoptosis. This was quasi experiment using post test with non-equivalent control group 
design. Simvastatin cytotoxic activity  was evaluated using MTT assay. Furthermore, 
the effect of simvastatin on cyclin D1 expression and apoptosis were evaluated using 
flow cytometry using antibody monoclonal anti-cyclin D1 and annexin V-Pi, respectively. 
The results showed that simvastatin had cytotoxic activity on T47D breast cancer cell 
lines with an IC50 value of 25.25 ± 1.61 µg/mL. Moreover, simvastatin in concentration 
range from 6.31 to 50.5 µg/mL decreased the cyclin D1 expression with an EC50 value of 
18.96±4.42 µg/mL and induced apoptosis with an EC50 value of  26.96 ± 6.05 µg/mL. 
In conclusion, simvastatin inhibits T47D breast cancer cell growth through reduction of 
cyclin D1 expression and induction of apoptosis. 
ABSTRAK
Statin (HMG-CoA inhibitor) merupakan golongan obat yang digunakan untuk menurunkan 
kadar kolesterol plasma dan untuk mencegah jantung koroner. Penelitian praklinik dan 
klinik menunjukkan bahwa terapi statin dapat menurunkan risiko terjadinya kanker. 
Penelitian ini bertujuan mengkaji aktivitas sitotoksik simvastatin terhadap kultur sel kanker 
payudara T47D dan efeknya terhadap ekspresi cyclin D1 dan apoptosis.  Jenis penelitian 
ini adalah eksperimenal semu dengan rancangan post test with non equivalent control 
group. Aktivitas sitotoksi simvastatin diuji dengan metode  MTT assay. Selanjutnya efek 
simvastatin terhadap ekspresi cyclin D1 dan apoptosis dikaji menggunakan flowcytometry 
menggunakan antibody monoclonal anti-cyclin D1 dan annexin V-Pi. Hasil penelitian 
menunjukkan simvastatin mempunyai aktivitas sitotoksik terhadap sel kanker payudara 
T47D dengan nilai IC50 sebesar 25,25 ± 1,61 µg/mL. Simvastatin dengan kisaran 
konsentrasi  6,31 sampai 50,5 µg/mL mampu menurunkan ekspresi cyclin D1 dengan nilai 
EC50 sebesar 18,96 ± 4,42 µg/mL dan menginduksi apoptosis dengan nilai EC50 sebesar 
26,96 ± 6,05 µg/mL. Sebagai kesimpulan, simvastatin menghambat pertumbuhan sel 
kanker payudara T47D dengan menurunkan ekspresi cyclin D1 dan menginduksi apoptosis.
Keywords:  simvastatin - cytotoxic activity - cyclin D1 - apoptosis activity - T47D breast 
cancer cell lines
J Med Sci, Volume 49, No. 2, 2017 April: 47-55
J Med Sci, Volume 49, No. 2, 2017 April: 47-55
48
INTRODUCTION
Cancer can be defined as the rapid growth 
of body cells cause disorders thus growth 
beyond the limits of necessity and then invade 
and spread to other parts of the body. Breast 
cancer is one of the most common cancers that 
cause death in women in the world. In 2013 
Ministry of Health, Republic of Indonesia 
reported that the prevalence of breast 
cancer was the second highest in Indonesia, 
approximately 0.5% of total population, with 
the highest prevalence in Yogyakarta Special 
Region (2.4%).1 
Statin (HMG-CoA Inhibitors) is drugs 
used for decreasing  cholesterol level and 
prevent heart coroner disease.2 In Indonesia, 
82.3% patients with hypercholesterolemia 
still use statin as first choice drug with the 
most frequently used is simvastatin (42.8%) 
followed by rosuvastatin (27.9%) and 
atorvastatin (19.2%).3  Statin use is associated 
with 20% risk reduction of cancer.  Statin have 
protective effect on cancer survivors therapy 
for more than 4 years.4 Cohort study found 
that using simvastatin in patients diagnosed 
with breast cancer, could reduce the death rate 
of breast cancer.5 
Furthermore, the statins such as fluvastatin, 
atorvastatin and simvastatin can inhibit cell 
proliferation associated with decreasing 
synthesis of DNA and cell cycle arrest in G
1 
and G
2
/M by increasing the expression of 
p53 and p21 proteins and induces cell death 
with oxidative stress.6,7 Simvastatin could also 
induce antiproliferative effects and increase 
expression of caspase 3 in order to stimulate 
apoptosis.8,9 This study was conducted  to 
prove the cytotoxicity of simvastatin against 
T47D breast cancer cell lines and its effect on 
cyclin D
1
 expression and  apoptosis.
MATERIALS AND METHODS
Materials
Simvastatin, 4-(2-hydrocyethyl)-pipera-
zine-ethane) sulphonic acid (HEPES), 
RPMI 1640, fetal bovine serum (FBS) 10%, 
amphotericin B, penicillin-streptomycin, and 
trypsin were obtained from Sigma-Aldrich®. 
The T47D breast cancer cell lines was 
obtained from the Laboratory of Parasitology, 
Faculty of Medicine, Universitas Gadjah 
Mada, Yogyakarta. Other materials were 
doxorubicin (Ebewe), sodium dodecyl sulfate 
(SDS) (Gibco®), sodium bicarbonate (Nacalai 
Tesque), phosphate buffer saline (PBS) 
(Invitrogen®), MTT [3-(4,5-dimethylthiazol-
2-yl)-2.5-diphenyltetrazolium bromide] (Bio 
Basic Inc.®), HCl (Merck®), cyclin D1-PE 
(A-12) monoclonal antibody (Santa cruz 
biotechnology, INC), and annexin V fluos 
staining kit (Roche®). 
Cytotoxic activity assay 
The T47D breast cancer cell lines at 1 
x 105/mL were plated in 96 well microplate 
with 100 µL each well and incubated for 24 
hours in starvated  media. One hundred µL 
of simvastatin solution in concentration 50; 
25; 12.5; 6.25; 3.125; and 1.5625 µg/mL 
were added in triplicate and then incubated 
for 24 hours. The media in each well was 
changed with 100 μL new media and 10 μL 
MTT reagent was added in each well and then 
incubated for 4-6 hours in a CO
2 
incubator 
at 37°C. Followed after incubation, 100 µL 
SDS in HCl 10% was added in each well and 
incubated at room temperature for 12 hours. 
The absorbance  of each  well was recorded 
using ELISA reader at λ of 595 nm. The 
absorbance of each well was used to calculate 
the percentages of proliferation inhibition 
by comparing with the control cells without 
any compounds. The concentration inhibiting 
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50% (IC
50
) of the cell lines was determined by 
probit analysis. 
Expression of cyclin D1 assay
The T47D breast cancer cell lines were 
cultured in 6 well plates at 5x105 cells per well. 
Each well was added with 2000 µL of each 
concentration series of simvastatin 0; 6.31; 
12.62; 25.25 and 50.48 µg/mL, and 400 µL 
of flowcytometry reagent. Cells suspension 
was transferred into the flowcytometry-tube 
through filter (nylon/glass cloth fabrics) using 
1 mL micropipette. The profile of cyclin D
1
 
expression was measured with flowcytometer 
and analyzed using FASC-Calibur program. 
Data were displayed in percentage of cyclin 
D
1 
expression in each treatment groups. The 
effect on cyclin D
1
 expression was assessed on 
the concentration inhibiting 50% expression 
(EC
50
) which determined by probit analysis.  
Apoptosis induction assay
The T47D breast cancer cell lines were 
cultured at 5x105 in 6 well plates. Each well was 
added with 2000 µL from each concentration 
series of simvastatin 0; 6.31; 12.62; 25.25 and 
50.48 µg/mL and doxorubicin 0.15 µg/mL. 
Solutions were prepared using incubation 
buffer 10 mM Hepes/NaOH pH 7.4; 140 mM 
NaCl and 5 mM CaCl2. Labeling solution for 
sample consisting of 15 to 30 μL of annexin 
V plus 1.5 mL of incubation buffer and 30 
µL of PI. Incubation cells were placed at the 
dark room for 10-15 minutes at a temperature 
of 15-25°C. Apoptosis was analyzed using 
FACS-Calibur program to obtain  distribution 
of the survived cell, apoptotic and necrotized 
cell on  all treatment group. The apoptosis 
induction activity was assessed on the 
concentration inducing 50% apoptosis (EC
50
) 
which determined by probit analysis.  
Statistical analysis
Data of IC
50
 an EC
50
 were presented as 
mean ± SD. Data of cyclin D1 expression 
and apoptosis induction were presented as 
percentage and compared using analysis of 
variance (ANOVA) followed by post hoc 
Bonferroni or Tamhane. A p value <0.05 was 
considered as statistically significant. 
RESULTS
Cytotoxic activity assay 
The inhibitory concentration 50% (IC
50
) 
of simvastatin and doxorubicin on T47D 
breast cancer cell lines were 25.25±1.61 and 
0.15±0.016 µg/mL, respectively (TABLE 1). 
These results showed that simvastatin had 
cytotoxic activity on T47D breast cancer cell 
lines, although its activity was lower than that 
doxorubicin as positive control (p<0.05). 
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TABLE 1. The percentage of T47D cell lines  proliferation inhibition (%) and the IC
50 
(mean ± SD) 
of simvastatin and doxorubicin
Drug
Concentration 
(µg/mL)
Replication
Mean IC
50
1 2 3
Inhibition IC
50
 Inhibition IC
50
 Inhibition IC
50
 
Simvastatin 50 89.45
27.03
90.44
24.78
91.39
23.92 25.25±1.61
25 51.28 45.73 58.52
12.5 21.25 20.66 20.92
6.3 12.68 26.45 18.60
3.1 1.98 26.22 11.76
1.6 2.46 5.56 9.06
Doxorubicin 0.25 75.71
0.17
80.53
0.14
80.15
0.15 0.15±0.016
0.13 38.51 69.17 56.64
0.06 16.19 14.67 5.14
0.03 2.46 2.74 -6.25
0.02 -10.84 -9.49 -9.02
Expression of cyclin D1 assay
The cyclin D
1
 expression of T47D 
breast cancer cell line after incubation with 
simvastatin is presented in  FIGURE 1. At 
the left side showed population of cells that 
did not express cyclin D
1
, and the right side 
showed population of cells that expressed 
cyclin D
1
.
FIGURE 1.  Cyclin D1 expression measured with flowcytometry in (a) control group without simvastatin, 
(b) simvastatin 6.31 µg/mL, (c) simvastatin 12.62 µg/mL, (d) simvastatin 25.25 µg/mL (e) 
simvastatin 50.48 µg/mL. 
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TABLE 2.  Cyclin D
1
 expression of T47D cells (%) after incubation with simvastatin for 24 
hours. 
Treatment
Concentration 
(µg/mL)
Cyclin D
1
 expression 
(Mean ± SD %)
p EC
50 
(µg/mL)
Control 0 65.89±0.73
0.000*
Simvastatin 6.31 59.98±1.81b 18.96±4.42
12.62 54.97±3.42b
25.25 45.01±3.96ab
50.48 25.23±13.72a
*:ANOVA;  a:  p<0.05, ANOVA followed by post hoc Bonferroni, compared with control; 
 b:  p<0.05, ANOVA followed by post hoc Bonferroni, compared with simvastatin  
  50.48 µg/mL.
Apoptosis induction assay
The apoptosis of T47D breast cancer 
cell line after incubation with simvastatin is 
presented in  FIGURE 2. Lower left showed 
live cells population, lower right showed 
apoptotic cells, and upper right showed 
necrotic cells.
FIGURE 2.  Apoptosis induction measured with flowcytometry after 24 hours incubation in  (a) control group without 
simvastatin, (b) simvastatin 6.31 µg/mL, (c) simvastatin 12.62 µg/mL, (d) simvastatin 25.25 µg/mL, (e) 
simvastatin 50.48 µg/mL, and (f) doxorubicin 0.15 µg/mL as positive control. Lower left: live cells pop-
ulation, lower right: apoptotic cells, upper right: necrotic cells
TABLE 3 shows the T47D breast 
cancer cells apoptosis after incubation with 
simvastatin for 24 hours. The simvastatin 
IC
50
 value (25.25 µg/mL) obtained from the 
cytotoxic activity assay was also used as one 
of the tested concentration  for apoptosis 
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assay. Simvastatin increased cells apoptosis 
in a concentration-dependent manner with 
the EC
50
 value of  26.96 ± 6.05 µg/mL. 
This finding indicated that incubation with 
simvastatin induces apoptosis in T47D breast 
cancer cells. 
TABLE 3. Mean of apoptotic cell of T47D cells (%) after giving simvastatin or doxorubicin for 24 hours
Treatment
Concentration 
(µg/mL)
Mean of apoptotic 
T47D cells (%) ± SD
p EC
50 
(µg/mL)
Control 0 4.82±0.92
0.000*
Simvastatin 6.31 20.87±4.55 26.96± 6.05
12.62 19.60±11.79
25.25 31.60±8.62
50.48 82.39±0.54ab
Doxorubicin 0.15 66.94±2.97ab
*: ANOVA Test; a: p<0.05, ANOVA continued post hoc Tamhane, compared with control; b: p<0.05, ANOVA 
continued post hoc Tamhane, compared with simvastatin 6.31 µg/mL.
DISCUSSION
Cytotoxic activity of simvastatin 
The T47D breast cancer cell lines was 
used in this study due to its high homogeneity 
and its simplicity replaceable with frozen 
stock contamination observed. Therefore 
these cells are often used for in vitro cancer 
studies.10  The results showed that incubation 
with simvastatin at concentrations from 50 
to 1.5625 µg/mL (119.45-3.73 µM) for 24 
hours inhibited T47D cell lines proliferation. 
This finding was consistent with other in vitro 
studies conducted by some authors. Lee et 
al.11 showed that incubation with simvastatin 
at concentrations from 0 to 500 µM (0-209.3 
µg/mL) for 24 and 48 hours inhibited the bile 
duct cancer cells proliferation. The incubation 
with simvastatin at concentration from 15 to 
120 µM (6.27 to 50.22 µg/mL) for 24 and 
28 also inhibited lung cancer A549 cells 
proliferation.12,13 Furthermore,  Huang et al. 
14 reported that incubation with simvastatin 
at concentration from 2 to 16 µM  for 24-
72 hours inhibited the HepG2 and Huh7 
cell line growth. The proliferation inhibition 
of ECC-1 and Ishikawa cell lines were also 
observed after incubation with simvastatin at 
concentration from 0.01 to 50 µM (0.0041 to 
20.92 µg/mL).15
According to American National Cancer 
Institute (NCI),  a compound is considered to 
have cytotoxic effect on cancer cell lines if its 
IC
50
 lower than 50 µg/mL.16 Furthermore, a 
compound could be classified as a very active, 
active and moderate potential anticancer 
compound if they have IC
50
 value < 5, 5-10 
and 11-30 µg/mL, respectively.17  Based on 
this criteria, simvastatin with an IC
50
 value 
of 25.25±1.61 µg/mL could be classified as 
a moderate potential anticancer compound. 
The IC
50
 of statin group on several cancer 
cell lines in different incubation period has 
been reported in the previous studies. The 
IC
50
 of simvastatin on MDM-231, SKBr3 
and MCF7 cancerous cell varied from 1.26 to 
91 µM,18   whereas on A549 cancerous cells 
was  45 µM  and on HeLa cell line was 9.14 
µM.12,19  Other statin drug, fluvastatin also 
showed cytotoxic effect against C6 glioma 
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cancer cells.18 In addition, atorvastatin was 
active against  NCI-H292 cancer cells with an 
IC
50
 value of 5.54 µg/mL20 and lovastatin was 
active against MDAMB468 and MDAMB231 
cancer cells  with IC
50
 values of 8 μg/mL and 
5 μg/mL, respectively.21
Effect of simvastatin on cyclin D1 expression 
Simvastatin decreased cyclin D
1
 expressi-
on of T47D breast cancer cell lines in a 
concentration-dependent manner (TABLE 
2). This finding was similar with study 
conducted by Liang et al. 22 which showed 
that simvastatin at concentration range 
from 12.5 to 50 µM (5.23 to 20.92 µg/mL) 
induced cell cycle arrest of NCI-H460 cancer 
cells through reduction of cyclin D
1
 and 
CDK4 expression and enhancement of  P21 
inhibitors CKD expression. Simvastatin also 
decreased cyclin D
1 
expression and CDK 
on hepatocellular cancer cell lines (Hep3B 
and Huh-7).23  Another study reported that 
simvastatin induced apoptosis in the HepG2 
and Huh7 cancer cell lines and its activity was 
accompanied by inhibition of CDK and cyclin 
D
1
, whereas CDK inhibitors p19 and p27 were 
enhanced.24 Other statins such as lovastatin 
also could affect the cell cycle by decreased 
cyclin D1-CDK 4 expression and increased 
p21WAF1/CIP1 expression on MCF-7 cells.2
Apoptosis induction activity of simvastatin 
Simvastatin increased cells apoptosis 
in a concentration-dependent manner. This 
finding indicated that simvastatin induced 
apoptosis in T47D breast cancer cell lines. 
This finding similar with previous studies 
conducted by some authors. Gopalan et al.25 
demonstrated that incubation with simvastatin 
at concentration range from 0.625-5.0 µM for 
three days induced apoptosis of MCF7 and 
MDA-MB-231 cancer cell line via activation 
of JNK/CHOP/DR5 signaling pathway. 
Ghosh-Choudury et al.26 also demonstrated 
that simvastatin attenuated the antiapoptotic 
Bcl
XL
 expression and induced depression of 
phosphatase and tensin homologous (PTEN) 
expression through NFκB to inhibit breast 
cancer growth. In addition, Koyuturk et al.27 
reported that simvastatin induced apoptosis 
through involvement of JNK in breast 
cancer cells independent of their ER or p53 
expression status. Simvastatin also suppressed 
PI3K/Akt/mTOR pathway by enhancing 
PTEN expression and by further sequentially 
dephosphorylating downstream cascades 
including Akt, mTOR, p70S6K, S6RP and 
4E-BP1. Furthermore, simvastatin inhibited 
MAPK/ERK pathway by dephosphorylating 
sequential cascades such as c-Raf, MEK1/2 
and ERK1/2.28
CONCLUSION
Simvastatin shows cytotoxic activity  on 
T47D breast cancer cell lines with an IC
50
 value 
of 25.25 µg/mL.  Furthermore, simvastatin 
decrease cyclin D1 expression with an EC
50 
value of  18.96 µg/mL, and induce apoptosis 
with an EC
50
 value of 26.96 µg/mL.
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